Xenetic Biosciences
XBIO
5 hedge funds and large institutions have $62K invested in Xenetic Biosciences in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.31% less ownership
Funds ownership: 1.27% → 0.97% (-0.31%)
16% less capital invested
Capital invested by funds: $73.8K → $62K (-$11.7K)
29% less funds holding
Funds holding: 7 → 5 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$4K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$44 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$11.7K |
| 2 |
SPIA
Steward Partners Investment Advisory
New York
|
-$7.16K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.49K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$41 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $50.3K | +$4K | +990 | +9% |
|
|
JEST
2
JTC Employer Solutions Trustee
St Helier,
Jersey
| $11K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $741 | -$11.7K | -2,893 | -94% |
|
|
4
Bank of America
Charlotte,
North Carolina
| $45 | +$44 | +11 | New |
|
5
Morgan Stanley
New York
| $4 | – | – | – |
|
|
SPIA
6
Steward Partners Investment Advisory
New York
| – | -$7.16K | -1,900 | Closed |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | -$3.49K | -925 | Closed |
|
|
8
Wells Fargo
San Francisco,
California
| – | -$41 | -11 | Closed |
|
XBIO Hedge Fund Activity: Q2 2024 in Review
5 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q2 2024, worth a combined $62K — down 16% from $73.8K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of XBIO and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Geode Capital Management, adding an estimated $4K. The largest seller was UBS Group, cutting an estimated $11.7K.
- 5 institutional investors held Xenetic Biosciences (XBIO) as of Q2 2024, down from 7 in Q1 2024.
- Funds reported $62K of Xenetic Biosciences stock for Q2 2024, down 16% quarter-over-quarter.
- 1 fund opened new Xenetic Biosciences positions in Q2 2024 and 3 closed out, a net change of -2 holders.
- The largest Xenetic Biosciences buyer in Q2 2024 was Geode Capital Management, an estimated $4K added.
- The largest Xenetic Biosciences seller in Q2 2024 was UBS Group, an estimated $11.7K sold.
Based on aggregated 13F filings for Q2 2024.